|

NEOK002 RDE Clinical Trials

1 actively recruiting trial across 1 location

No change since August 2026

Pipeline

Phase 1: 1

Top Sponsors

  • NEOK Bio, Inc.1

Indications

  • Locally Advanced (Unresectable) or Metastatic Solid Tumors1
  • Cancer1

Orlando, Florida1 trial

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona DDU

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.